ArticleDiagnostic pathology2026
CLDN18.2 expression identifies a gastric-type phenotype and a potential therapeutic target in pulmonary invasive mucinous adenocarcinoma.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Claudin 18 Immunohistochemistry Expression in Salivary Gland Neoplasms: Limited Potential as a Therapeutic Biomarker.Head and neck pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsThis study aimed to investigate the clinicopathological and immunophenotypic significance of Claudin18.2 (CLDN18.2) in pulmonary invasive mucinous adenocarcinoma (IMA), with particular focus on its association with gastric-type differentiation and potential implications for diagnosis and targeted therapy.
methodsImmunohistochemistry for CLDN18.2, MUC5AC, MUC6, and PD-L1 (22C3-TPS) was performed in 117 surgically resected lung IMAs. Associations with clinicopathological parameters and overall survival were analysed. Correlation analyses among CLDN18.2, MUC5AC, and MUC6 expression were conducted using Spearman's rank coefficients to assess the relationship between CLDN18.2 and gastric-type mucin phenotype.
resultsCLDN18.2 expression was detected in 71 of 117 tumors (60.7%), including 42 with high (35.9%) and 29 with low (24.8%) expression. MUC5AC and MUC6 positivity was observed in 75.2% and 34.2% of cases, respectively, while all tumors were PD-L1 negative. Spread through air spaces (STAS) was less frequent in CLDN18.2-positive (40.8% vs. 60.9%, P = 0.034) and MUC5AC-positive tumors (42% vs. 69%, P = 0.012). High CLDN18.2 expression was associated with earlier pathological stage (81% vs. 68%) and fewer nodal metastases (4.8% vs. 18%). CLDN18.2 expression correlated positively with MUC5AC (ρ = 0.469, P < 0.0001) and MUC6 (ρ = 0.43, P < 0.0001). Neither CLDN18.2 nor MUC5AC had prognostic impact, whereas MUC6 positivity tended to indicate shorter overall survival (P = 0.088).
conclusionsCLDN18.2 is frequently expressed in lung IMA and is closely associated with gastric-type mucin differentiation and reduced aerogenous spread. Although not prognostic, its consistent expression in PD-L1-negative tumors suggests a distinct biological subset and supports the potential use of CLDN18.2 as a biomarker for molecular stratification and therapeutic exploration in this rare subtype of lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.